BPC-157

Discovery and Structure

BPC-157 — short for "Body Protection Compound 157" — is a synthetic pentadecapeptide with the amino acid sequence GEPPPGKPADDAGLV. It was first isolated in the early 1990s at the University of Zagreb by researchers investigating why human gastric juice appears to protect the stomach lining from its own corrosive acidity. The parent protein, a 62-amino-acid "body protection compound," was identified in gastric secretions and BPC-157 is a stable 15-residue fragment derived from it.

Unlike most peptides, BPC-157 is exceptionally stable in gastric juice — it survives stomach acid and does not require stabilizing modifications. This property makes it one of the few peptides that remains bioactive via oral administration in animal models, though most human protocols use subcutaneous injection to ensure reliable dosing.

Preclinical Research Landscape

The peer-reviewed literature on BPC-157 is dominated by rodent studies, with over 100 papers published since the late 1990s. Research has clustered around several themes:

• Tendon and ligament healing. Multiple rat-model studies have reported accelerated repair of transected Achilles tendons and medial collateral ligaments when BPC-157 is administered systemically, often within 14 days.
• Gastrointestinal repair. Early studies focused on gastric ulcers, inflammatory bowel models, and fistula healing — areas consistent with the compound's gastric origin.
• Angiogenesis. BPC-157 appears to upregulate vascular endothelial growth factor (VEGF) expression and promote capillary formation in wounded tissue.
• Central nervous system. Smaller bodies of work have explored potential neuroprotective effects in models of traumatic brain injury and dopaminergic toxicity.

The proposed mechanism most frequently cited is modulation of the nitric oxide (NO) system, with secondary effects on growth hormone receptor expression and the dopaminergic system. Importantly, nearly all of this work has been conducted by a small cluster of research groups, and independent replication remains limited — a caveat frequently raised in reviews of the compound.

Human Clinical Data

Despite its popularity in wellness circles, BPC-157 has an extremely thin human evidence base. As of 2026, only a handful of small pilot trials and case series have been published, most focused on inflammatory bowel disease and knee pain. No Phase 3 trials have been completed. This gap between preclinical enthusiasm and clinical validation is the single most important context for anyone evaluating BPC-157.

Regulatory Status

In September 2023, the U.S. FDA placed BPC-157 on its Category 2 bulk drug substance list, meaning it cannot be compounded by Section 503A or 503B pharmacies in the United States. The FDA cited concerns about safety data, immunogenicity risk, and insufficient characterization. BPC-157 is also prohibited in-competition by the World Anti-Doping Agency (WADA) under the S0 class (non-approved substances).

It remains widely available through research-chemical suppliers, but this is not a regulated medical supply chain — product quality, purity, and actual peptide content vary considerably. See our guide to gray-market peptide sourcing for more context on this issue.

Practical Considerations

Research-literature protocols typically use 200–500 mcg twice daily via subcutaneous injection, often near the site of injury when a localized effect is desired. Cycle lengths of 4–12 weeks are common in anecdotal protocols, though these durations are not derived from clinical trial data. BPC-157 is frequently paired with TB-500 in community protocols targeting connective tissue, though no head-to-head or combination trials exist in humans.

Commonly reported side effects are mild and transient — injection-site irritation, occasional nausea, and fatigue. The long-term safety profile is unknown because long-term human studies have not been conducted.

The Bottom Line

BPC-157 is one of the most-studied peptides in preclinical literature and one of the least-studied in humans. The animal data is genuinely interesting; the human data is almost absent. For researchers and practitioners following the space, the meaningful milestones to watch are independent replication of key rodent findings and the first adequately powered human trials — neither of which had arrived by early 2026.